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Introduction
Mantle cell lymphoma (MCL) is an aggressive and difficult to treat subtype of B-cell nonHodgkin`s lymphoma (NHL) which accounts for approximately 6% of all NHL cases. 1 Historically, MCL had a poor prognosis with a median survival of about 3 years when treated with conventional dose chemotherapy. The administration of the anti-CD20 monoclonal antibody rituximab in combination with conventional chemotherapy was shown to increase responses but it had only a minor impact on survival. 2, 3 Intensified treatment approaches including the hyper-CVAD regimen and high-dose chemotherapy with autologous stem cell support result in an improvement of progression-free and overall survival. [4] [5] [6] However, this therapeutic approach is not feasible for the large proportion of patients with MCL presenting at an advanced age or with co-morbidities. Moreover, after first relapse, prognosis of MCL patients is considered to be very poor with a median survival of approximately 1 to 2 years, 7 which underscores the urgent need for novel therapeutic interventions.
In recent years, focus on inhibition of the proteasome by its specific inhibitor bortezomib (Btz) has become an emerging anti-tumour strategy approved by the US Food and Drug Administration first in relapsed multiple myeloma and later in the treatment of relapsed MCL. The proteasome is responsible for the degradation of intracellular proteins, including several proteins involved in cell cycle control and the regulation of apoptosis. 8 Preclinical studies have shown that the proteasome inhibitor Btz decreases proliferation, induces apoptosis, enhances the activity of chemotherapy and radiation, and reverses chemoresistance in a variety of hematologic and solid malignancy models in vitro and in vivo. Five phase II trials have now documented single-agent activity of Btz in relapsed MCL, with response rates ranging between 30 and 50% including some patients achieving a complete response (CR). [13] [14] [15] [16] [17] [18] Rituximab has been tested as a single agent for the treatment of previously untreated and relapsed MCL and was shown to induce partial remissions in 27 -38% of patients. [19] [20] [21] In various preclinical studies, evidence was obtained for additive and possibly synergistic tumor cell killing of various combinations of Btz, dexamethasone, and rituximab. [22] [23] [24] This provided the basis for our investigation to explore Btz, rituximab, and dexamethasone (BORID) in patients with relapsed and chemotherapy-refractory MCL.
Design and Methods

Patient selection
Patients Patients were excluded if signs of severe congestive heart failure (New York Heart Failure Guidelines Class III/IV) or active infection were present. Patients were also excluded if they had evidence of central nervous system involvement of the lymphoma, known HIV positivity, any psychiatric illness that could limit compliance with study requirements, other primary malignancy (other than squamous or basal cell skin cancer or cervical cancer in situ) diagnosed within 5 years, or were pregnant or breast feeding.
Patients were required to give written informed consent.
Study design
This was a single-center, phase II study of Btz combined with rituximab and dexamethasone in patients with relapsed/refractory MCL. The primary endpoint was efficacy of the regimen defined by the response rate. Secondary objectives were tolerability and efficacy defined as progression-free (PFS) and overall survival (OS). The study was approved by the institutional review board of the Medical University of Vienna. A summary of this study was registered at www.clinicaltrials.gov as #NCT00261612.
Treatment
Btz was administered at a dose of 1.3mg/m 2 as an intravenous bolus push over 3 to 5 seconds twice weekly for two weeks (days 1, 4, 8 and 11) followed by a 10-day rest period (days 12 -21) of a three-week cycle. Doses were repeated if the absolute neutrophil count was > 1.0 x 10 9 /L and the platelet count was >30x10 9 /L. The proptocol included prophylactic intravenous fluids of 500 to 1000 ml of saline, which was administered before each dose of Btz.
Rituximab 
Evaluation of response and toxicity
Baseline evaluations included clinical examination, bone marrow aspirate and biopsy, and computer tomography of chest, abdomen and pelvis, and head and neck, if indicated. Patients were restaged every three cycles and then every 3 months afterwards until progression.
Positron emission tomography tests were repeated in patients with positive nuclear imaging studies at baseline.
Response criteria for patients enrolled onto the study followed the guidelines previously defined. 25 All responses were classified as either complete remission (CR), partial remission (PR), stable disease (SD) or PD. In patients with measurable gastrointestinal involvement by endoscopy, the patient was considered as having a CR if all lesions were resolved and multiple random biopsies were negative.
PFS was calculated from the date of BORID initiation until the date of progression or death.
OS was calculated from the time of initiation of therapy and death from any cause or last follow-up. Survival curves were plotted using the Kaplan-Meier method.
Toxicity was recorded according to the National Cancer Institute Common Terminology
Criteria for Adverse Events (CTCAE), Version 3.0.
Results
Patient population
Sixteen patients (male = 13, female = 3) with relapsed/refractory MCL were enrolled in this phase II study. Patient had received a median of 3 prior lines of therapy (range, 1-6) including CHOP-polychemotherapy (100%), rituximab (88%), high-dose chemotherapy followed by autologous stem cell transplantation (31%), a fludarabine-containing regimen (31%), and a thalidomide-combination (50%; either combined with rituximab 26 or rituximab plus chemotherapy). Three patients were refractory to their last line of therapy preceding study treatment. Additional patients' characteristics and disease related features are summarized in Table 1 . According to the IPI risk group, 27 10 patients (62.5%) were at high-risk. Based upon the MIPI, 28 14 patients (87.5%) were at intermediate or high risk.
Response and Survival
A median of 4.4 treatment cycles (range, 2-6) was administered. Applying standard response criteria, 25 we observed an objective response to the BORID treatment combination in 13 of the 16 patients (overall response rate of 81.3%) including CR in 7 patients (43.8%) and PR in 6 patients (37.5%). FDG-PET scanning was performed in 6 of the patients achieving a CR and confirmed the remission status by absence of metabolic activity in all 6 patients. The Ki-67 growth fraction was available in 13 patients only, but it appeared that achievement of CR was independent of the proliferative activity (4 CR among 9 patients with Ki67 >30%; 1 CR among 4 patients with Ki-67 <30%). A detailed presentation of patient characteristics, prior therapy, and response is given in Table 2 .
Median PFS and OS were 12.1 months and 38.7 months, respectively ( Figure 1 ). The association between quality of response and PFS is illustrated in Figure 2 : Patients achieving a CR had significantly longer PFS (with 5 patients being still in CR beyond 48 months) compared to patients reaching only a PR. In patients achieving a CR, median PFS and OS
have not yet been reached, which was significantly different from the outcome in patients reaching only PR (Figure 3 ).
Toxicity
A summary of adverse events is outlined in fludarabine, 41 and even polychemotherapy. 42 Although the actual numbers of MCL patients in these trials are very small, there appears to be improved efficacy compared to Btz alone. We believe that our trial adds important information to these reports because of the long-term follow-up demonstrating durable benefit particularly for those patients achieving a CR.
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